Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
11.54 (USD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 79.204 | 86.16 | 97.074 | 122.473 | 205.197 | 206.625 | 102.814 | 88.268 | 160.88 | 47.741 | 32.053 | 41.706 | 41.882 | 22.763 |
| Cost of Revenue
| 2.371 | 2.973 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 76.833 | 83.187 | 97.074 | 122.473 | 205.197 | 206.625 | 102.814 | 88.268 | 160.88 | 47.741 | 32.053 | 41.706 | 41.882 | 22.763 |
| Gross Profit Ratio
| 0.97 | 0.965 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 163.524 | 164.522 | 174.111 | 136.756 | 142.213 | 94.856 | 57.451 | 40.461 | 23.189 | 18.74 | 16.841 | 15.115 | 11.547 | 9.716 |
| General & Administrative Expenses
| 52.887 | 45.482 | 32.536 | 27.356 | 26.246 | 23.441 | 20.749 | 16.966 | 13.543 | 10.016 | 6.183 | 5.302 | 0 | 6.105 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 52.887 | 45.482 | 32.536 | 27.356 | 26.246 | 23.441 | 20.749 | 16.966 | 13.543 | 10.016 | 6.183 | 5.302 | 5.036 | 6.105 |
| Other Expenses
| 0 | 0.083 | 1.994 | 6.62 | 8.819 | 4.793 | 2.333 | 1.719 | 1.307 | 0.283 | 0.598 | 0 | 5.036 | 0.309 |
| Operating Expenses
| 216.411 | 210.004 | 206.647 | 164.112 | 168.459 | 118.297 | 78.2 | 57.427 | 36.732 | 28.756 | 23.024 | 20.417 | 16.583 | 15.821 |
| Operating Income
| -137.207 | -123.844 | -109.573 | -41.639 | 36.738 | 88.328 | 24.614 | 30.841 | 124.148 | 18.985 | 9.029 | 21.289 | 25.299 | 6.942 |
| Operating Income Ratio
| -1.732 | -1.437 | -1.129 | -0.34 | 0.179 | 0.427 | 0.239 | 0.349 | 0.772 | 0.398 | 0.282 | 0.51 | 0.604 | 0.305 |
| Total Other Income Expenses Net
| 6.212 | 1.656 | 1.994 | 6.62 | 8.819 | 4.793 | 2.333 | 1.719 | 1.307 | 0.283 | 0.598 | -0.008 | 1.089 | 0.791 |
| Income Before Tax
| -130.995 | -122.188 | -107.579 | -35.019 | 45.557 | 93.121 | 26.947 | 32.56 | 125.455 | 19.268 | 9.627 | 21.399 | 23.31 | 7.747 |
| Income Before Tax Ratio
| -1.654 | -1.418 | -1.108 | -0.286 | 0.222 | 0.451 | 0.262 | 0.369 | 0.78 | 0.404 | 0.3 | 0.513 | 0.557 | 0.34 |
| Income Tax Expense
| 2.821 | -0.433 | -28.583 | 1.149 | -0.826 | 21.165 | 9.237 | 10.894 | 46.463 | -15.17 | -0.221 | 0 | 3.161 | -0.157 |
| Net Income
| -133.816 | -121.755 | -78.996 | -36.168 | 46.383 | 71.956 | 17.71 | 21.666 | 78.992 | 34.438 | 9.627 | 21.399 | 23.31 | 7.904 |
| Net Income Ratio
| -1.69 | -1.413 | -0.814 | -0.295 | 0.226 | 0.348 | 0.172 | 0.245 | 0.491 | 0.721 | 0.3 | 0.513 | 0.557 | 0.347 |
| EPS
| -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.017 |
| EPS Diluted
| -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.8 | -0.67 | 0.52 | 0.59 | 0.015 |
| EBITDA
| -123.476 | -120.954 | -109.573 | -41.639 | 36.738 | 88.328 | 24.614 | 30.841 | 124.148 | 18.985 | 9.029 | 21.579 | 25.881 | 7.818 |
| EBITDA Ratio
| -1.559 | -1.404 | -1.129 | -0.34 | 0.179 | 0.427 | 0.239 | 0.349 | 0.772 | 0.398 | 0.282 | 0.517 | 0.618 | 0.343 |